EG 427

About EG 427

EG 427 is dedicated to developing next-generation precision molecular therapies to address chronic diseases at their local root in a safe and durable way. Their mission is to provide safe, efficacious, and affordable therapies for patients with severe localized chronic diseases using a powerful gene therapy platform based on non-replicative Herpes Simplex Virus 1 (nrHSV-1) vectors.

Products & Services

DNA Medicine Platform:A gene therapy platform utilizing non-replicative Herpes Simplex Virus 1 (nrHSV-1) vectors for safe, specific, and durable expression of disease-modifying transgenes, targeting peripheral nervous system disorders.

Pipeline of Vectors:A range of vectors targeting various indications, with the most advanced project focusing on Type C neurons for the treatment of underserved bladder disorders, primarily affecting women and minorities.

Specialties

Gene Therapy Non-Replicative Herpes Simplex Virus 1 (nrHSV-1) Vectors Peripheral Nervous System Disorders DNA Medicine Platform Targeted Vector Engineering Non-replicative Herpes Simplex Virus 1 (nrHSV-1) Vectors DNA Medicines Targeted Neuronal Effects

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 29160000 MR: - FA: €27 million FAN: 29160000	D: 2025-02-20 FD: 2025-02-20	3 investors
2	RT: Series B T: - FT: Series B	A: 29700000 MR: - FA: €27 million FAN: 29700000	D: 2025-02-20 FD: 2025-02-20	3 investors
3	RT: Series A T: - FT: Series A	A: 19800000 MR: - FA: €18 million FAN: 19800000	D: 2023-07-13 FD: 2023-07-13	2 investors
4	RT: Series A T: - FT: Series A	A: 18000000 MR: - FA: €18 million FAN: 18000000	D: 2023-07-13 FD: 2023-07-13	2 investors

Series B Latest

2025-02-20

$29.2M

3 investors (Pro only)

Series B 2025-02-20

$29.7M

Series A 2023-07-13

$19.8M

View 3 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Philippe Chambon, MD, PhD

Founder, Chairman & CEO

P

Philippe Chambon

Founder, Chairman & CEO

A

Alberto Epstein

Founder & CSO

C

Cornelia Haag-Molkenteller

CMO

S

Samuel Salot

COO

T

Teddy Jégu

VP Research

View 17 more team members with Pro

Unlock Full Team Directory

Recent News

EG 427 Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised